Bovine AAV as a lung-directed vector: what the paper reports
Molecular Therapy Advances, published online 5 October 2026, December 2026 issue. DOI 10.1016/j.omta.2026.201859.
Mouse IV lung
Preferential
Type I pneumocytes and lung endothelium
Production
AAV9-like yield
Thermal margin 7 to 10 C lower
Human sera
Intermediate
Below AAV2/AAV4
Above AAV5/AAV9
Source
5 October 2026
December 2026 issue
Novartis authors
Preclinical only. Open-access paper, Europe PMC PMC13734831. Detectable off-lung expression is reported; liver signal stayed below AAV9.
Facts from the open-access paper (PMC13734831; DOI 10.1016/j.omta.2026.201859). Online 5 October 2026, December 2026 issue.
Bovine AAV targets mouse lung.
Human neutralization is intermediate.
A recent paper in Molecular Therapy Advances evaluates a bovine AAV capsid as a lung-directed vector (DOI 10.1016/j.omta.2026.201859). It was published online on 5 October 2026, in the December 2026 issue. The findings are preclinical and come from mice, human cells and human sera.
What was reported
The paper, titled Bovine AAV: A promising vector for pulmonary gene therapy, starts from a known barrier. Efficient systemic delivery to the lung is hard, and pre-existing immunity limits conventional capsids.
In adult C57BL/6J mice, intravenous bovine AAV gave robust and preferential lung transduction, comparable with AAV4. The authors report predominant targeting of alveolar type I pneumocytes and pulmonary endothelial cells.
In primary human lung-resident cells, bovine AAV was particularly effective in microvascular endothelial cells. The authors note that AAV4 transduced that target poorly in vitro.
On manufacturing, the authors report scalable production, with yield, purification performance, capsid quality and genome integrity comparable to AAV9. They also report capsid unfolding temperatures 7 C to 10 C lower than AAV9, and a 9 C to 10 C lower onset temperature for genome release.
They say the narrower thermal stability margins may have implications for large-scale production, formulation, storage and transportation. In sera from healthy adults in the United States and Switzerland, neutralization frequencies were lower than AAV2 and AAV4 but higher than AAV5 and AAV9.
In mice previously immunized with a pool of human and non-human-primate-derived AAV capsids, including AAV4, bovine AAV kept its in vivo transduction efficiency. All authors are or were affiliated with Novartis Biomedical Research, and the paper states they have shares of the company.
What this does and does not show
These are preclinical findings. They do not establish clinical performance, safety or superiority over any existing capsid.
The paper is open access under a CC BY-NC-ND licence and is available in Europe PMC as PMC13734831. In the mouse intravenous study, the authors report a dose of 1.0 x 10^13 vg/kg, or 2.5 x 10^11 vg per 25 g mouse. They used n = 5 per group and an ss-CAG-GFP cassette.
This GTC page is a review of a recent paper, not same-week breaking news. The work was published online on 5 October 2026, about five weeks before this page.
Intermediate neutralization is not low neutralization. Bovine AAV was neutralized more often than AAV5 and AAV9 in these sera, so a patient screening question remains.
What GTC would ask
For developers: is your target tissue lung endothelium or alveolar type I cells, and does your seroprevalence panel show a real gap for conventional capsids? Without both, a divergent capsid has no clear job to do.
Ask what the benchmark should be. The paper compares to AAV4 for mouse lung transduction, to AAV9 for production, and to AAV2, AAV4, AAV5 and AAV9 for neutralization. Check that your comparison set matches your own program.
For investors: ask about capsid ownership and freedom to operate. The authors are or were Novartis employees and report holding shares of the company.
The paper also reports some off-target distribution, with detectable expression in the liver, heart, kidney and brain. Liver transduction remained substantially lower than that of AAV9, according to the authors.
Practical takeaway
If your target tissue and seroprevalence panel suggest a conventional capsid will struggle, a divergent capsid may deserve a small benchmarking study. Include thermal stability and off-lung biodistribution in that comparison, not yield alone.
Related GTC reading
Frequently asked questions
What does the bovine AAV paper report?
The paper reports that intravenous bovine AAV transduced mouse lung preferentially, comparable with AAV4, targeting alveolar type I pneumocytes and pulmonary endothelial cells. It also reports AAV9-comparable production and intermediate human serum neutralization.
How does human neutralization of bovine AAV compare?
In sera from healthy adults in the United States and Switzerland, bovine AAV neutralization frequencies were lower than AAV2 and AAV4 but higher than AAV5 and AAV9.
Does bovine AAV work in the presence of pre-existing immunity?
In mice previously immunized with a pool of human and non-human-primate-derived AAV capsids, including AAV4, bovine AAV maintained in vivo transduction efficiency. This is a mouse result and not a human immunity result.
Is bovine AAV production comparable to AAV9?
The authors report that bovine AAV showed scalable production, with yield, purification performance, capsid quality and genome integrity comparable to AAV9.
Does this paper show bovine AAV is better than other capsids?
No. The findings are preclinical, and the paper does not establish clinical performance or superiority. It positions bovine AAV as a candidate for lung delivery where pre-existing immunity limits conventional serotypes.
Sources
- Ivan et al., Bovine AAV: A promising vector for pulmonary gene therapy, Molecular Therapy Advances, published online 5 October 2026, December 2026 issue, DOI 10.1016/j.omta.2026.201859. Open access via Europe PMC PMC13734831. - 2026-10-05
- Europe PMC full text, PMC13734831, retrieved 10 November 2026 - 2026-10-05
Join the GTC Expert Network
Independent Experts
Independent experts in cell & gene therapy: share knowledge, help build a report, or contribute quietly. Build authority and get called for paid consulting work. Join free.
Early R&D Experts
Early R&D ExpertsContribute target validation, vector engineering, or transgene design expertise. Get matched to paid consulting work through content you help create.
Join FreeCMC Experts
CMC ExpertsContribute scale-up, tech transfer, or GMP manufacturing expertise. Get matched to paid consulting work through content you help create.
Join FreeRegulatory Affairs Experts
Regulatory Affairs ExpertsContribute IND/BLA strategy or regulatory liaison expertise. Get matched to paid consulting work through content you help create.
Join FreeCommercial & Strategy Experts
Commercial & Strategy ExpertsContribute due diligence, licensing, or market access expertise. Get matched to paid consulting work through content you help create.
Join FreeEnabling Technology Experts
Enabling Technology ExpertsContribute bioprocessing hardware, analytical tooling, or supply-chain expertise. Get matched to paid consulting work through content you help create.
Join FreeAI Transformation Experts
AI Transformation ExpertsContribute agentic workflow, LLM, or AI-driven vector design expertise. Get matched to paid consulting work through content you help create.
Join FreeIndustry Representatives
Industry professionals in cell & gene therapy: de-risk your pipeline with expert input on demand, exactly when your program needs it. Join free.
Drug Developers
Drug DevelopersFounders, CSOs, VPs of R&D
Practical guides spanning vector design through commercialization, plus direct access to the expert network that wrote them.
Join FreeInvestors / VCs
Investors / VCsVC Fund Managers, Family Offices, Angels
Due diligence frameworks and strategic intelligence for evaluating CGT assets, from experts who do this diligence for a living.
Join FreeTechnology Developers
Technology DevelopersFounders, Licensing & Commercial Leads
IP protection and platform strategy guides for enabling technologies, plus the network that built them.
Join FreeCDMOs / CROs
CDMOs / CROsBD, Operations & Technical Leads
Partner selection, vendor evaluation, and operational excellence guides, sourced from the CGT organisations that use them.
Join FreeVendors / Suppliers
Vendors / SuppliersCommercial & Technical Leads
Market intelligence and partnership strategies for supply chain companies serving cell and gene therapy.
Join FreeStrategy Consultants
Strategy ConsultantsConsultants, Market Access Advisors
Spot the problems before they cost your clients - join the network that shapes what GTC covers next.
Join FreeAI Transformation Partners
AI Transformation PartnersAI/ML Consultancies, Digital Transformation Firms
AI education, implementation, and consulting for operational excellence in cell and gene therapy - for companies building or buying AI capability.
Join FreeWhere the analysis comes from. Industry teams get expert input on demand; independent experts build authority and get called for paid consulting work.
See more of our work in Google Search
Google lets you pick the sites you want to see more often in Top Stories. Add Gene Therapy Consultancy to your list, and our daily gene therapy news will show up higher for you.